Payment overview · 2025
General Payments
$395.86
10 reported records · 3 companies
Healthcare provider profile · identity verified
Luis A Couret, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FRANKLIN PARK, IL · NPI 1134218399
Verified facts
What the public records show
CMS Open Payments records show Luis A Couret, M.D. received $395.86 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $172.81 | 43.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.32 | 41.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.73 | 15.1% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.86 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $142.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $59.73 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.46 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.46 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 841 | 196 |
| Furosemide | Furosemide | 398 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 360 | 92 |
| Losartan Potassium | Losartan Potassium | 348 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 304 | 71 |
| Metformin Hcl | Metformin Hcl | 279 | 82 |
| Gabapentin | Gabapentin | 252 | 48 |
| Omeprazole | Omeprazole | 239 | 71 |
| Eliquis | Apixaban | 229 | 29 |
| Glipizide | Glipizide | 203 | 51 |
| Donepezil Hcl | Donepezil Hcl | 199 | 30 |
| Lisinopril | Lisinopril | 196 | 48 |
| Nifedipine Er | Nifedipine | 195 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 30 |
| Simvastatin | Simvastatin | 162 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 26 |
| Potassium Chloride | Potassium Chloride | 154 | 27 |
| Carvedilol | Carvedilol | 150 | 29 |
| Trazodone Hcl | Trazodone Hcl | 150 | 37 |
| Tramadol Hcl | Tramadol Hcl | 146 | 23 |
| Alprazolam | Alprazolam | 144 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 25 |
| Meloxicam | Meloxicam | 129 | 62 |
| Finasteride | Finasteride | 124 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 45 |
| Sertraline Hcl | Sertraline Hcl | 119 | 16 |
| Azithromycin | Azithromycin | 111 | 86 |
| Amiodarone Hcl | Amiodarone Hcl | 105 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 67 |
| Famotidine | Famotidine | 97 | 13 |
| Alendronate Sodium | Alendronate Sodium | 94 | 27 |
| Memantine Hcl | Memantine Hcl | 91 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 67 |
| Mirtazapine | Mirtazapine | 79 | 16 |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 21 |
| Allopurinol | Allopurinol | 71 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 68 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 19 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 19 |
| Ozempic | Semaglutide | 61 | 12 |
| Metolazone | Metolazone | 58 | suppressed |
| Trulicity | Dulaglutide | 57 | suppressed |
| Prednisone | Prednisone | 55 | 31 |
| Enalapril Maleate | Enalapril Maleate | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 16 |
| Baclofen | Baclofen | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 12 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Acyclovir | Acyclovir | 45 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 32 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 20 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Lactulose | Lactulose | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 19 |
| Amoxicillin | Amoxicillin | 27 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Levocarnitine | Levocarnitine | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 18 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Constulose | Lactulose | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 15 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.86 · 10 records | Amgen Inc. | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, OTEZLA, PAXLOVID, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error